FDA approves new indication for Regeneron, Sanofi’s DupixentThe FDA has approved a new indication for Dupixent, providing an option for patients age 12-to-17 years old with moderate to severe atopic dermatitis. Adlon Therapeutics gets FDA green light for Adhansia XR capsulesAdlon Therapeutics' Adhansia XR capsules offer a new option for ADHD patients. Cynthia Schwalm to join Hikma's board Cynthia Schwalm, who has held positions at Ipsen, Eisai, Amgen and J&J, is joining Hikma's board June 1. Janssen gets FDA nod for Spravato The approval of Spravato nasal spray to help tackle treatment-resistant depression marks the first time the FDA has approved its active ingredient, esketamine, for any use. FDA approves new indication for Janssen's Darzalex Janssen's Darzalex split-dosing regimen provides an option for multiple myeloma patients to split the first infusion over two consecutive days. Novartis gets FDA nod for Egaten Egaten is the only Food and Drug Administration-approved drug for the treatment of fascioliasis in patients six years old and older. Janssen's nasal spray for depression clears FDA committee If approved, Spravato will offer the first new mechanism of action in 30 years to treat adults with treatment-resistant depression. Mayne Pharma launches Lexette foam Mayne is debuting a foam treatment for adult patients with plaque psoriasis. Sanofi, Regeneron lower prices for Praluent The lower-priced Praluent is expected to be available for pharmacies to order in early March. J&J to include cost information in TV drug ads Janssen will include both the list price and potential patient out-of-pocket costs in future direct-to-consumer TV ads. First Previous 40 41 42 43 44 Next Last
